NASDAQ:EVLO

Evelo Biosciences Competitors

$11.56
0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$11.10
Now: $11.56
$11.91
50-Day Range
$9.71
MA: $11.45
$13.69
52-Week Range
$3.55
Now: $11.56
$19.93
Volume176,279 shs
Average Volume276,802 shs
Market Capitalization$616.55 million
P/E RatioN/A
Dividend YieldN/A
Beta1.46

Competitors

Evelo Biosciences (NASDAQ:EVLO) Vs. XNCR, ALXO, CYRX, RCUS, PBH, and DRNA

Should you be buying EVLO stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Evelo Biosciences, including Xencor (XNCR), ALX Oncology (ALXO), Cryoport (CYRX), Arcus Biosciences (RCUS), Prestige Consumer Healthcare (PBH), and Dicerna Pharmaceuticals (DRNA).

Evelo Biosciences (NASDAQ:EVLO) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Earnings & Valuation

This table compares Evelo Biosciences and Xencor's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A$-85,470,000.00($2.67)-4.33
Xencor$156.70 million15.63$26.88 million$0.4691.87

Xencor has higher revenue and earnings than Evelo Biosciences. Evelo Biosciences is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Evelo Biosciences and Xencor, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evelo Biosciences02302.60
Xencor20702.56

Evelo Biosciences presently has a consensus price target of $20.00, suggesting a potential upside of 73.01%. Xencor has a consensus price target of $47.1111, suggesting a potential upside of 11.48%. Given Evelo Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Evelo Biosciences is more favorable than Xencor.

Profitability

This table compares Evelo Biosciences and Xencor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evelo BiosciencesN/A-159.17%-88.81%
Xencor-113.40%-13.56%-12.03%

Institutional & Insider Ownership

84.6% of Evelo Biosciences shares are held by institutional investors. 7.3% of Evelo Biosciences shares are held by company insiders. Comparatively, 3.7% of Xencor shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Evelo Biosciences has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Xencor has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

Summary

Evelo Biosciences beats Xencor on 7 of the 13 factors compared between the two stocks.

Evelo Biosciences (NASDAQ:EVLO) and ALX Oncology (NASDAQ:ALXO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of current ratings and target prices for Evelo Biosciences and ALX Oncology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evelo Biosciences02302.60
ALX Oncology00703.00

Evelo Biosciences currently has a consensus price target of $20.00, suggesting a potential upside of 73.01%. ALX Oncology has a consensus price target of $90.6667, suggesting a potential upside of 49.29%. Given Evelo Biosciences' higher possible upside, equities analysts plainly believe Evelo Biosciences is more favorable than ALX Oncology.

Profitability

This table compares Evelo Biosciences and ALX Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evelo BiosciencesN/A-159.17%-88.81%
ALX OncologyN/AN/AN/A

Earnings and Valuation

This table compares Evelo Biosciences and ALX Oncology's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A$-85,470,000.00($2.67)-4.33
ALX OncologyN/AN/AN/AN/AN/A

Institutional and Insider Ownership

84.6% of Evelo Biosciences shares are held by institutional investors. Comparatively, 73.5% of ALX Oncology shares are held by institutional investors. 7.3% of Evelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

ALX Oncology beats Evelo Biosciences on 4 of the 7 factors compared between the two stocks.

Cryoport (NASDAQ:CYRX) and Evelo Biosciences (NASDAQ:EVLO) are both transportation companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk and analyst recommendations.

Volatility & Risk

Cryoport has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Evelo Biosciences has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cryoport and Evelo Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cryoport00703.00
Evelo Biosciences02302.60

Cryoport currently has a consensus target price of $72.00, suggesting a potential upside of 39.62%. Evelo Biosciences has a consensus target price of $20.00, suggesting a potential upside of 73.01%. Given Evelo Biosciences' higher possible upside, analysts clearly believe Evelo Biosciences is more favorable than Cryoport.

Earnings & Valuation

This table compares Cryoport and Evelo Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cryoport$33.94 million69.29$-18,330,000.00($0.55)-93.76
Evelo BiosciencesN/AN/A$-85,470,000.00($2.67)-4.33

Cryoport has higher revenue and earnings than Evelo Biosciences. Cryoport is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cryoport and Evelo Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cryoport-55.87%-17.68%-11.32%
Evelo BiosciencesN/A-159.17%-88.81%

Institutional and Insider Ownership

88.3% of Cryoport shares are held by institutional investors. Comparatively, 84.6% of Evelo Biosciences shares are held by institutional investors. 11.5% of Cryoport shares are held by insiders. Comparatively, 7.3% of Evelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Cryoport beats Evelo Biosciences on 9 of the 13 factors compared between the two stocks.

Evelo Biosciences (NASDAQ:EVLO) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership.

Profitability

This table compares Evelo Biosciences and Arcus Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evelo BiosciencesN/A-159.17%-88.81%
Arcus Biosciences-112.63%-27.43%-20.96%

Risk and Volatility

Evelo Biosciences has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.

Insider & Institutional Ownership

84.6% of Evelo Biosciences shares are held by institutional investors. Comparatively, 60.6% of Arcus Biosciences shares are held by institutional investors. 7.3% of Evelo Biosciences shares are held by company insiders. Comparatively, 19.7% of Arcus Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Evelo Biosciences and Arcus Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A$-85,470,000.00($2.67)-4.33
Arcus Biosciences$15 million156.54$-84,710,000.00($1.93)-17.17

Arcus Biosciences has higher revenue and earnings than Evelo Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Evelo Biosciences and Arcus Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evelo Biosciences02302.60
Arcus Biosciences00903.00

Evelo Biosciences presently has a consensus target price of $20.00, indicating a potential upside of 73.01%. Arcus Biosciences has a consensus target price of $51.50, indicating a potential upside of 55.45%. Given Evelo Biosciences' higher probable upside, equities research analysts clearly believe Evelo Biosciences is more favorable than Arcus Biosciences.

Summary

Arcus Biosciences beats Evelo Biosciences on 8 of the 13 factors compared between the two stocks.

Evelo Biosciences (NASDAQ:EVLO) and Prestige Consumer Healthcare (NYSE:PBH) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Insider and Institutional Ownership

84.6% of Evelo Biosciences shares are owned by institutional investors. 7.3% of Evelo Biosciences shares are owned by company insiders. Comparatively, 1.2% of Prestige Consumer Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Evelo Biosciences has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Prestige Consumer Healthcare has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Valuation & Earnings

This table compares Evelo Biosciences and Prestige Consumer Healthcare's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A$-85,470,000.00($2.67)-4.33
Prestige Consumer Healthcare$963.01 million2.34$142.28 million$2.9615.28

Prestige Consumer Healthcare has higher revenue and earnings than Evelo Biosciences. Evelo Biosciences is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Evelo Biosciences and Prestige Consumer Healthcare, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evelo Biosciences02302.60
Prestige Consumer Healthcare03302.50

Evelo Biosciences presently has a consensus price target of $20.00, indicating a potential upside of 73.01%. Prestige Consumer Healthcare has a consensus price target of $87.60, indicating a potential upside of 93.72%. Given Prestige Consumer Healthcare's higher probable upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than Evelo Biosciences.

Profitability

This table compares Evelo Biosciences and Prestige Consumer Healthcare's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evelo BiosciencesN/A-159.17%-88.81%
Prestige Consumer Healthcare17.03%13.76%4.80%

Summary

Prestige Consumer Healthcare beats Evelo Biosciences on 8 of the 12 factors compared between the two stocks.

Evelo Biosciences (NASDAQ:EVLO) and Dicerna Pharmaceuticals (NASDAQ:DRNA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation.

Profitability

This table compares Evelo Biosciences and Dicerna Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evelo BiosciencesN/A-159.17%-88.81%
Dicerna Pharmaceuticals-88.81%-71.72%-16.60%

Insider & Institutional Ownership

84.6% of Evelo Biosciences shares are held by institutional investors. Comparatively, 80.6% of Dicerna Pharmaceuticals shares are held by institutional investors. 7.3% of Evelo Biosciences shares are held by company insiders. Comparatively, 11.3% of Dicerna Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Evelo Biosciences and Dicerna Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evelo Biosciences02302.60
Dicerna Pharmaceuticals00703.00

Evelo Biosciences currently has a consensus target price of $20.00, indicating a potential upside of 73.01%. Dicerna Pharmaceuticals has a consensus target price of $39.1429, indicating a potential upside of 35.16%. Given Evelo Biosciences' higher possible upside, equities research analysts clearly believe Evelo Biosciences is more favorable than Dicerna Pharmaceuticals.

Risk & Volatility

Evelo Biosciences has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Comparatively, Dicerna Pharmaceuticals has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.

Earnings & Valuation

This table compares Evelo Biosciences and Dicerna Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A$-85,470,000.00($2.67)-4.33
Dicerna Pharmaceuticals$23.90 million92.48$-120,460,000.00($1.76)-16.45

Evelo Biosciences has higher earnings, but lower revenue than Dicerna Pharmaceuticals. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Dicerna Pharmaceuticals beats Evelo Biosciences on 7 of the 13 factors compared between the two stocks.


Evelo Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Xencor logo
XNCR
Xencor
1.2$42.26flat$2.45 billion$156.70 million-30.19
ALX Oncology logo
ALXO
ALX Oncology
1.9$60.73flat$2.44 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Cryoport logo
CYRX
Cryoport
1.9$51.57flat$2.35 billion$33.94 million-88.91
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.13flat$2.35 billion$15 million-17.35Unusual Options Activity
News Coverage
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.22flat$2.25 billion$963.01 million14.04
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$28.96flat$2.21 billion$23.90 million-17.99Analyst Report
Unusual Options Activity
News Coverage
Gap Down
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.6$50.68flat$2.08 billionN/A0.00Insider Selling
Analyst Revision
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$26.15flat$2.01 billion$103.54 million-19.66Insider Selling
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$124.77flat$2.00 billionN/A-11.27
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.44flat$2.00 billionN/A-19.87
Amarin logo
AMRN
Amarin
1.6$5.02flat$1.98 billion$429.76 million-100.38Analyst Revision
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.22flat$1.94 billion$410,000.00-5.92Analyst Report
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$59.69flat$1.91 billionN/A-25.40Increase in Short Interest
MacroGenics logo
MGNX
MacroGenics
1.2$31.83flat$1.91 billion$64.19 million-10.17Decrease in Short Interest
News Coverage
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.73flat$1.90 billion$34.51 million-17.72
Kura Oncology logo
KURA
Kura Oncology
1.6$28.59flat$1.89 billionN/A-17.54
FibroGen logo
FGEN
FibroGen
1.8$19.91flat$1.82 billion$256.58 million-7.63Analyst Report
High Trading Volume
News Coverage
MORF
Morphic
1.3$55.08flat$1.79 billion$16.98 million-35.31Insider Selling
Decrease in Short Interest
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05flat$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00flat$1.77 billion$14.87 million-14.18Increase in Short Interest
News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.70flat$1.77 billion$26.87 million-12.93Insider Selling
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.89flat$1.77 billion$1.63 billion14.37Analyst Report
Decrease in Short Interest
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.61flat$1.71 billion$428.41 million15.38News Coverage
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.70flat$1.68 billion$392.76 million13.15Analyst Upgrade
Analyst Revision
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.06flat$1.64 billionN/A-6.43Increase in Short Interest
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.87flat$1.63 billion$145.97 million-7.23
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.29flat$1.60 billion$2.34 million-9.87
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.15flat$1.60 billionN/A0.00Analyst Revision
News Coverage
Generation Bio logo
GBIO
Generation Bio
1.8$28.30flat$1.60 billionN/A0.00Insider Selling
Increase in Short Interest
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.35flat$1.57 billion$320,000.00-8.40News Coverage
uniQure logo
QURE
uniQure
1.7$34.07flat$1.53 billion$7.28 million-9.04Insider Selling
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$24.95flat$1.51 billion$175.34 million-14.68Analyst Downgrade
Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.52flat$1.50 billion$82.27 million-18.34
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$32.24flat$1.50 billionN/A0.00Analyst Upgrade
News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$41.84flat$1.47 billionN/A0.00
OLMA
Olema Pharmaceuticals
1.6$36.14flat$1.45 billionN/A0.00Increase in Short Interest
News Coverage
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$32.37flat$1.45 billionN/A0.00Insider Selling
Increase in Short Interest
Endo International logo
ENDP
Endo International
1.3$6.26flat$1.44 billion$2.91 billion-9.21
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.51flat$1.42 billion$19.89 million-13.45Analyst Report
News Coverage
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$21.71flat$1.42 billion$73.41 million-4.59
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.56flat$1.41 billion$6.20 million-14.28News Coverage
Zymeworks logo
ZYME
Zymeworks
1.8$30.38flat$1.40 billion$29.54 million-8.06Unusual Options Activity
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$34.85flat$1.39 billionN/A-145.21
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$26.68flat$1.38 billion$4.23 million-19.76Increase in Short Interest
ATBPD
Antibe Therapeutics
0.1$3.57flat$1.38 billion$7.51 million-5.95Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.52flat$1.38 billionN/A-2.98
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$56.67flat$1.32 billionN/A0.00Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$34.35flat$1.26 billionN/A0.00Analyst Upgrade
News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$30.01flat$1.25 billionN/A0.00Analyst Report
Increase in Short Interest
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$33.68flat$1.25 billionN/A0.00
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.